文献速递术前评估与围术期医学疼痛医学

艾司洛尔、抗伤害作用及其在常规麻醉中潜在阿片节约角色

Esmolol, Antinociception, and Its Potential Opioid-Sparing Role in Routine Anesthesia Care.
PubMed 文献 · Reg Anesth Pain Med · 2018-01-01

本文为叙述性论述,回顾艾司洛尔在围术期β阻滞指南中的定位,简述支持其抗伤害作用的研 究,提出可能机制,并展望其作为多模式全静脉麻醉组分用于术中及阿片节约的前景。

要点

  • 艾司洛尔迄今未显示直接镇痛或麻醉特性,但近期研究提示其可能具有抗伤害和术后阿片节约效应。
  • 围术期β阻滞指南(非心脏手术相关)是当前艾司洛尔围术期应用的参考框架。
  • 区域麻醉与急性疼痛医学医师可在推广该护理进步中发挥引领作用。

核心结论

  • 艾司洛尔可能具有抗伤害和术后阿片节约效应,但尚未显示直接镇痛或麻醉特性,其常规术中应用(作为多模式全静脉麻醉组分)及阿片节约影响尚待前瞻性验证。

研究设计与样本

  • 本文为Daring Discourse叙述性论述,未报告系统检索范围或样本量。

主要发现

  • 近期研究提示艾司洛尔可能具有抗伤害和术后阿片节约效应。
  • 艾司洛尔迄今未显示任何直接镇痛或麻醉特性。
  • 传统术后镇痛主要依赖阿片类药物,其自身存在不良反应和药物流行病学后果。

临床怎么用

  • 在围术期β阻滞指南(非心脏手术相关)框架下审视艾司洛尔的使用。
  • 可考虑将艾司洛尔作为多模式全静脉麻醉的组分用于术中,以探索阿片节约效应。
  • 区域麻醉与急性疼痛医学医师可牵头推广这一护理进步。

局限性

  • 本文为叙述性论述,未提供系统检索策略或定量证据汇总。
  • 艾司洛尔的抗伤害与阿片节约效应主要基于近期研究提示,尚缺乏直接镇痛或麻醉特性的证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

β-Adrenergic blockade is an important mechanism for reducing morbidity and mortality in patients with hypertension and heart failure. Esmolol has been used widely for its chronotropic and antihypertensive effects. However, there has been recent inquiry regarding perioperative esmolol use and nociceptive modulation. Conventional postoperative analgesic treatment has relied primarily on opioids, which present their own adverse effects and pharmacoepidemiologic repercussions. Esmolol, to date, has not shown any direct analgesic or anesthetic properties; however, recent studies suggest that esmolol may have antinociceptive and postoperative opioid-sparing effects. In this Daring Discourse narrative, we describe the role of esmolol in current perioperative β-blockade guidelines (related to noncardiac surgery), briefly describe studies supporting the antinociceptive effects of esmolol, propose mechanisms for esmolol antinociception, and forecast potential routine esmolol use intraoperatively (as part of a multimodal total intravenous anesthetic) and its effects on opioid sparing. The reading audience of regional anesthesiologists and acute pain medicine physicians is uniquely positioned to take a lead role in promulgating this care advance amid (i) the unwanted effects of the opioid epidemic and (ii) the uncertain notion of whether routine general anesthesia care (with fentanyl) may indirectly be contributing to the epidemic.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Bahr MP, Williams BA. Esmolol, Antinociception, and Its Potential Opioid-Sparing Role in Routine Anesthesia Care. Reg Anesth Pain Med. 2018. PMID: 30216240. doi:10.1097/AAP.0000000000000873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。